CATALYSTYahoo Finance • 5h ago
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to BuyYahoo Finance report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
Why OABI Stock dropped -2.29% Today — RQD Quant Desk Flash
$5.11 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.08
OmniAb Inc. (OABI) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $760.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OABI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, OmniAb Inc. (NASDAQ: OABI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.11 (-2.29% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #433 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OABI compare to NRC and ABSI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OABI?
▼
Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.08 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OABI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY OABI SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.77-1.7% Next Q
36
Q2 (-2Q)Grade E$4.69-1.7% Next Q
39
Q3 (-1Q)Grade D$4.61+10.8% Next Q
41
CurrentGrade D$5.11-6.5% Hist 90D α
44
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OABI Turnaround Squeeze
While OABI currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.67) and Max Pain ($5.37) forces dealer call-delta covering toward $5.70.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OABI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OABI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OABI Stock dropped -2.29% Today — RQD Quant Desk Flash
OmniAb Inc. (OABI) dropped -2.29% to $5.11, trading at 92% of its 52-week range ($1.3 – $5.43). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 92% of its 52-week range ($1.3 – $5.43) with RSI-14 at 61 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.11 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live OABI Headlines & Catalysts
MARKET WIREMoomoo • 8h ago
OmniAb(OABI) Stock Options Chain | Quotes & NewsMoomoo report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 11h ago
OmniAb: A Self-Funding Option Book On 433 Partner ProgramsSeeking Alpha report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
CATALYSTChartMill • 14h ago
OmniAb Inc. (NASDAQ:OABI) Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News PressureChartMill report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 17h ago
OmniAb (OABI) Q3 Results Keep Cash Progress In FocusYahoo Finance report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 20h ago
OmniAb (OABI) Stock Forum and DiscussionMoomoo report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 23h ago
OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow (NASDAQ:OABI) 2026-10-06Seeking Alpha report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
OmniAb (OABI) Stock Price Slips As Q3 Results Raise Cash Burn QuestionsSimply Wall St report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
OmniAb, Inc. Q3 2026 Earnings Call SummaryMoby summary of OmniAb, Inc.'s Q3 2026 earnings call
CATALYSTYahoo • 3d ago
OmniAb (OABI) Q3 2026 Earnings Call TranscriptRevenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OABI)
- ✓Walkthrough of OABI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OABI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +262.41%⚡ TESTING RESISTANCE
2026-11-02O $5.28H $5.28L $5.11C $5.11VOL 1.68M
RES: $5.41SUP: $2.51SMA50: $4.67SMA200: $2.72
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OABI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -29.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OABI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OABI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OABI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OABI)
Health Care Rank #433 of 1016
⚔️ NRC vs OABI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OABI vs. NRC, ABSI, MXCT, ICLR)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, OmniAb Inc. (OABI) ranks #433 by composite RQD confidence (44/100, grade D) and #392 by equity capitalization ($760.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with OABI at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OABI
ACTIVE
OmniAb Inc. | D | 44/100 | — | — | -22.6% | -2.29% | $760.4M | Benchmark Subject |
| NRC NRC Health | C+ | 67/100 | 44.8x | — | 21.0% | +1.45% | $519.6M | /nrc-vs-oabi → |
| ABSI Absci Corporation | D | 45/100 | — | — | -35.0% | -8.02% | $2.08B | /absi-vs-oabi → |
| MXCT MaxCyte Inc. | D- | 35/100 | — | 96.0% | -27.1% | -8.09% | $178.5M | /mxct-vs-oabi → |
| ICLR ICON plc | B- | 71/100 | 71.9x | — | 3.1% | -1.91% | $16.50B | /iclr-vs-oabi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001846253In its most recent audited fiscal period (FY2025, filed 2025-12-31), OmniAb Inc. (OABI) reported GAAP revenue of $18.7M (-29.3% vs. FY2024 revenue of $26.4M , and -45.4% cumulative change since FY2023) , GAAP net income of -$64.8M, operating cash flow of -$36.5M, and free cash flow of -$37.0M (+10.9% YoY). On the balance sheet, OABI closed FY2025 with $300.9M in total assets against $0 in total debt (Altman Z-Score: 12.19, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $18.7M | -$64.8M | -$36.5M | -$37.0M | $300.9M | — |
| FY2024 (FY) | 2024-12-31 | $26.4M | -$62.0M | -$39.7M | -$41.5M | $325.6M | — |
| FY2023 (FY) | 2023-12-31 | $34.2M | -$50.6M | $2.3M | $2.3M | — | — |
3. OABI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, OmniAb Inc. (NASDAQ: OABI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.11 (-2.29% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #433 in composite RQD confidence.
How does OABI compare to NRC and ABSI in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OABI?
Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OABI trading relative to its 50-day, 200-day, and 52-week technical levels?
OABI last traded at $5.11 (-2.29% on volume of 2,114,034 shares), positioning the stock +9.42% above its 50-day simple moving average ($4.67) and +87.87% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.30 to $5.43, OABI sits at the 92.3% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.47 to $5.75).
OABI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OABI stock moving today?
Why OABI Stock dropped -2.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 44/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
OABI — OmniAb Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:33:11Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, OABI scores 44 out of 100 (grade D; verdict "Roarable Sell — Underperform / Distribution Warning"). The five pillars break down as follows:
- Fundamental Cash Engine: 9 / 20. Per the RQD rating, this pillar reflects ROIC of -22.6% and an FCF yield of -4.87%. For an investor, negative returns on invested capital and negative free-cash-flow yield mean the business is currently consuming rather than generating capital relative to its value.
- Whale 13F Flow: 16 / 20. Per the RQD rating, this is the strongest pillar, described as reflecting institutional accumulation and options positioning. This is the one area where the rating signals constructive positioning, though the underlying 13F and options detail is not itemized in the source data.
- Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow, and scores very low. For a prospective investor this is a meaningful caution flag, since the insider-flow signal is weak.
- Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves with the market and carries sector-level exposure, without a clear defensive or regime-favored profile.
- Forensic Balance Sheet: 8 / 20. Per the RQD rating, the Altman Z-Score is 12.19, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. The high Z-Score points to low near-term bankruptcy risk, but the weak Piotroski score signals poor fundamental quality trends.
Taken together, the investment case rests on institutional interest and a solid balance-sheet cushion, offset by persistent operating losses, weak insider signals, and low fundamental quality. Upside depends on the business reaching cash-flow breakeven; the valuation tradeoff is that the current price reflects a company not yet generating positive returns, so the stock trades on future expectations rather than present earnings.
Business
OmniAb Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Resarch industry. The source data does not describe its products, customers, or revenue model beyond its reported revenue figures. Market capitalization is listed as $0.8B in the company profile.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $18.7M | $-69.0M | $-64.8M | N/A | $-37.0M | $25.5M | N/A |
| FY 2024 | $26.4M | $-74.5M | $-62.0M | N/A | $-41.5M | $27.6M | N/A |
| FY 2023 | $34.2M | $-69.4M | $-50.6M | N/A | $2.3M | N/A | N/A |
Revenue declined from $34.2M (FY 2023) to $26.4M (FY 2024) to $18.7M (FY 2025), while net losses persisted in every reported year. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -22.6%. Per the RQD rating, the Altman Z-Score is 12.19 (suggesting low distress risk) and the Piotroski F-Score is 2/9 (indicating weak fundamentals), with Debt/Equity at 0.5. Reported cash declined from $27.6M to $25.5M over the most recent year.
Recent Catalysts & News Wire Analysis
Recent headlines (per the news feed) include a Yahoo Finance item titled with a rating upgrade to Buy, a Seeking Alpha piece describing a "self-funding option book" across 433 partner programs, and a ChartMill report describing a Q3 2026 revenue beat and raised guidance offset by sell-the-news pressure. Other items include Yahoo Finance coverage of Q3 results focused on cash progress, and Moomoo options and forum pages. Several items are tagged as catalysts (green) and others as market wire (yellow).
Risk watch items: the news wire reports selling pressure following a revenue beat, and cash-progress framing signals that cash generation remains a central question. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Open Questions
- What are OmniAb's products, customers, and revenue sources, given that the source data provides only financial totals and a sector classification?
- What is the path to positive operating cash flow, given operating losses in every reported year and FCF of $-37.0M in FY 2025?
- Why did reported revenue decline across FY 2023–FY 2025, and what is driving the Q3 2026 revenue beat referenced in the news feed?
- What are the specific 13F, options, and insider trades underlying the whale-flow and insider-conviction pillar scores?
- What are the EPS, P/E, and EV/EBITDA figures, which are absent from the source data and would be needed to value the stock against earnings?
OABI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for OmniAb Inc. (OABI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 5h ago
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy Yahoo Finance report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 8h ago
OmniAb(OABI) Stock Options Chain | Quotes & News Moomoo report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 11h ago
OmniAb: A Self-Funding Option Book On 433 Partner Programs Seeking Alpha report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ChartMill • 14h ago
OmniAb Inc. (NASDAQ:OABI) Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News Pressure ChartMill report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 17h ago
OmniAb (OABI) Q3 Results Keep Cash Progress In Focus Yahoo Finance report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 20h ago
OmniAb (OABI) Stock Forum and Discussion Moomoo report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 23h ago
OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow (NASDAQ:OABI) 2026-10-06 Seeking Alpha report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
OmniAb (OABI) Stock Price Slips As Q3 Results Raise Cash Burn Questions Simply Wall St report covering OmniAb Inc. (OABI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OABI Bull vs. Bear Conversation Board — What's Your Call at $5.11?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OABI 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $4.60 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is OABI (D • RQD 44/100) a Buy at $5.23?
Welcome to the OABI (OmniAb Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.24 (-18.9%)
Spot @ $5.23 Pump the brakes on OABI — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on OABI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless OmniAb Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $6.64 (+27.0%)
Spot @ $5.23 OABI cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on OABI, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $5.23 (52-wk range $1.30 - $5.43), any beat on forward guidance forces shorts and underweight funds to chase.